ATLAS:卡非佐米、来那度胺和地塞米松的风险适应三联维持-仍在耸耸肩?

Oncology & Haematology Pub Date : 1900-01-01 DOI:10.17925/ohr.2022.18.2.96

Joseph K Franz, S. Lonial

{"title":"ATLAS:卡非佐米、来那度胺和地塞米松的风险适应三联维持-仍在耸耸肩?","authors":"Joseph K Franz, S. Lonial","doi":"10.17925/ohr.2022.18.2.96","DOIUrl":null,"url":null,"abstract":"ATLAS (ClinicalTrials.gov Identifier: NCT02659293) is a randomized phase III clinical trial comparing intensified carfilzomib, lenalidomide and dexamethasone (KRd) maintenance to standard-of-care, single-agent lenalidomide. The recently reported primary analysis showed a progression-free survival benefit for KRd. Whilst the study met its primary endpoint, closer analysis of its design and results is necessary before this intensified maintenance strategy can be adopted in clinical practice.","PeriodicalId":249239,"journal":{"name":"Oncology & Haematology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone – Still Shrugging?\",\"authors\":\"Joseph K Franz, S. Lonial\",\"doi\":\"10.17925/ohr.2022.18.2.96\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ATLAS (ClinicalTrials.gov Identifier: NCT02659293) is a randomized phase III clinical trial comparing intensified carfilzomib, lenalidomide and dexamethasone (KRd) maintenance to standard-of-care, single-agent lenalidomide. The recently reported primary analysis showed a progression-free survival benefit for KRd. Whilst the study met its primary endpoint, closer analysis of its design and results is necessary before this intensified maintenance strategy can be adopted in clinical practice.\",\"PeriodicalId\":249239,\"journal\":{\"name\":\"Oncology & Haematology\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology & Haematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/ohr.2022.18.2.96\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology & Haematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/ohr.2022.18.2.96","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

ATLAS (ClinicalTrials.gov识别码:NCT02659293)是一项随机III期临床试验，比较强化卡非佐米、来那度胺和地塞米松(KRd)维持与标准护理单药来那度胺的疗效。最近报道的初步分析显示，KRd的无进展生存期获益。虽然该研究达到了主要终点，但在临床实践中采用这种强化维持策略之前，有必要对其设计和结果进行更深入的分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone – Still Shrugging?

ATLAS (ClinicalTrials.gov Identifier: NCT02659293) is a randomized phase III clinical trial comparing intensified carfilzomib, lenalidomide and dexamethasone (KRd) maintenance to standard-of-care, single-agent lenalidomide. The recently reported primary analysis showed a progression-free survival benefit for KRd. Whilst the study met its primary endpoint, closer analysis of its design and results is necessary before this intensified maintenance strategy can be adopted in clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncology & Haematology

自引率

0.00%

发文量